Skip to main content
. 2021 Mar 5;11(11):5107–5126. doi: 10.7150/thno.54755

Figure 1.

Figure 1

Preparation of EXOs loaded with anti-angiogenesis peptide and efficiency of HUVEC delivery. (A) Schematic illustration of preparation of EXOKV11 by painting an anti-angiogenic peptide (KV11) on EXOs via the exosomal anchor peptide CP05. (B) Flow cytometry for measuring the binding efficiency of KV11-CP05 on EXOs. For checking cellular uptake, FITC-labeled KV11-CP05 was used. (C) EXOs were labeled with DiR and incubated with FITC- labeled KV11 (EXO+KV11) or FITC- labeled KV11-CP05 (EXOKV11) for 6 h at 4 °C. Each mixture was then added to HUVECs in culture. Representative confocal images from at least three different experiments show the cellular uptake of KV11 in HUVECs at 24 and 48 h. (D) EXO+KV11 and EXOKV11 prepared as in (C) were added to HUVECs in culture. After 24 or 48 h, cells were trypsinized for flow cytometry to analyze the cellular uptake efficiency of EXO+KV11 and EXOKV11. The red line represents the no-treatment control (Ctrl). The percentage of FITC-positive events out of total events is indicated in each histogram. Scale bars, 20 µm in (C).